Download PDF
Arzneimittelforschung 2012; 62(07): 307-312
DOI: 10.1055/s-0032-1309042
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Bioequivalence of Two Formulations of Escitalopram

S. Almeida
1   Medical Department, Grupo Tecnimede, Rua da Tapada Grande 2, Abrunheira, Portugal
2   Department of Pharmacology and Therapeutics, Universidad Autonoma de Barcelona
,
P. Pedroso
1   Medical Department, Grupo Tecnimede, Rua da Tapada Grande 2, Abrunheira, Portugal
,
A. Filipe
1   Medical Department, Grupo Tecnimede, Rua da Tapada Grande 2, Abrunheira, Portugal
,
R. I. Neves
1   Medical Department, Grupo Tecnimede, Rua da Tapada Grande 2, Abrunheira, Portugal
,
M. Tanguay
3   PharmaNet Canada, Inc., René-Lévesque Ouest Québec (Québec) Canada
,
A. Torns
4   Anapharm Europe S.L. c/ Encuny 22, Barcelona Spain
› Author Affiliations
Further Information

Publication History

received 23 January 2012

accepted 19 March 2012

Publication Date:
24 May 2012 (online)

    Permissions and Reprints

Abstract

Escitalopram, CAS registry number 128196-01-0 is an orally administrated selective serotonin reuptake inhibitor (SSRI).

The objective of this trial was to assess bioequivalence between an escitalopram formulation manufactured by Grupo Tecnimede and that of a European reference formulation, while evaluating both formulations’ tolerability as a secondary objective.

24 healthy subjects were enrolled in a single centre, randomised, single-dose, open-label, 2-way crossover study. Drug levels were determined by reverse liquid chromatography and detected by tandem mass spectrometry detection, LC-MS/MS method. Pharmacokinetic parameters used for bioequivalence assessment were determined from the drug concentration data using non-compartmental analysis.

Mean±Standard deviation (SD) Cmax values were 18.89±5.06 ng/mL and 18.45±5.05 ng/mL for reference and test, respectively. AUClast was 577.16±196.20 ng · h/mL after the administration of the reference and 577.69±220.88 ng · h/mL for the test. AUCinf was 595.66±203.80 ng · h/mL after the administration of the reference 596.19±235.47 ng · h/mL for the test.

The 90% confidence intervals obtained by analysis of variance were 92.38–103.38% for Cmax, 94.10–104.37% for AUClast and 93.80–104.09% for AUCinf, which were within the predefined acceptable range of 80.00–125.00%. Both formulations were well tolerated, with no major side effects and no relevant differences in safety profiles observed between the preparations.

The design of the study was adequate to determine the pharmacokinetic parameters of the test and the reference formulations. Bioequivalence between formulations was concluded both in terms of rate and extent of absorption.

Key words

escitalopram - bioequivalence - AUC - Cmax - CAS number 128196-01-0
 

  • References

  • 1 SPC, Summary of Product Characteristics Cipralex, 2011
    PubMed
  • 2 Murdoch D, Keam SJ. Spotlight on escitalopram in the management of major depressive disorder. CNS Drugs 2006; 20 (02) 167-170
    CrossrefPubMedSearch in Google Scholar
  • 3 EMA, European Medicines Agency. Guideline for the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**, 2010
    PubMedSearch in Google Scholar
  • 4 ICH Topic E6 (R1) Guideline for good clinical practice. Note for guidance on good clinical practice. CPMP/ICH/135795. London: 2002: 1-59
    Search in Google Scholar
  • 5 FDA . Guidance for industry: Bioanalytical method validation. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research; Rockville: 2001: 1-22
    Search in Google Scholar
  • 6 McKinnon RA, Evans AM. Cytochrome P450, 2. Pharmacogenetics. Aust J Hosp Pharm 2000; 30: 102-105
    PubMedSearch in Google Scholar